Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

PHASE4CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Transfusional Hemosiderosis
Interventions
DRUG

deferasirox:

Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.

Trial Locations (23)

10065

New York Presbyterian Hospital, New York

10595

New York Medical College, Valhalla

11040

Schneider Children's Hospital, New Hyde Park

17033

Penn State Children's Hospital, Hershey

19134

St Christopher's Hospital for Children, Philadelphia

21201

University of Maryland Greenebaum Cancer Center, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

30912

Medical College of Georgia, Augusta

60614

Children's Memorial, Chicago

63110

Washington University School of Medicine, St Louis

70118

Tulane University Health Sciences Center, New Orleans

73104

University of Oklahoma, Oklahoma City

77030

Texas Children's Cancer Center and Hematology Services, Houston

80045

University of Colorado Denver, Colorado Sickle Cell Treatment and Research Center, Aurora

94523

Bay Area Cancer Research Group, Pleasant Hill

94609

Children's Hospital and Research Center, Oakland

94304-1812

Stanford University, Palo Alto

06520

Yale University School of Medicine, New Haven

02115

Children's Hospital of Boston, Boston

02118

Boston Medical Center, Boston

07601

The Cancer Center at Hackensack University Medical Center, Hackensack

08901

Cancer Institute of New Jersey, New Brunswick

07503

St Joseph Children's Hospital, Paterson

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY